SENTRY-CD19

· Vironexis Biotherapeutics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SENTRY-CD19, covering 2026-03-30 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) [Phase 1, Phase 2]